

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>RA CAPITAL MANAGEMENT, L.P.</u>			2. Issuer Name and Ticker or Trading Symbol <u>Hemab Therapeutics Holdings, Inc. [COAG]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/04/2026					
200 BERKELEY STREET, 18TH FLOOR			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
(Street)								
BOSTON	MA	02116						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/04/2026		C		3,607,846	A	(1)	3,607,846	I	See footnotes ⁽²⁾⁽³⁾
Common Stock	05/04/2026		C		1,009,052	A	(1)	1,009,052	I	See footnotes ⁽²⁾⁽⁴⁾
Common Stock	05/04/2026		C		221,188	A	(1)	221,188	I	See footnotes ⁽²⁾⁽⁵⁾
Common Stock	05/04/2026		P		2,541,250	A	\$18	6,149,096	I	See footnotes ⁽²⁾⁽³⁾
Common Stock	05/04/2026		P		133,750	A	\$18	354,938	I	See footnotes ⁽²⁾⁽⁵⁾
Common Stock	05/05/2026		P		87,143	A	\$24.59 ⁽⁶⁾	6,236,239	I	See footnotes ⁽²⁾⁽³⁾
Common Stock	05/05/2026		P		10,268	A	\$25	6,246,507	I	See footnotes ⁽²⁾⁽³⁾
Common Stock	05/06/2026		P		14,611	A	\$23.77 ⁽⁷⁾	6,261,118	I	See footnotes ⁽²⁾⁽³⁾
Common Stock	05/06/2026		P		53,407	A	\$24.83 ⁽⁸⁾	6,314,525	I	See footnotes ⁽²⁾⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series A Preferred Stock	(1)	05/04/2026		C		64,680	(1)	(1)	(1)	Common Stock	1,422,960	(1)	0	I	See footnotes ⁽²⁾⁽³⁾
Series A Preferred Stock	(1)	05/04/2026		C		27,720	(1)	(1)	(1)	Common Stock	609,840	(1)	0	I	See footnotes ⁽²⁾⁽⁴⁾
Series B Preferred Stock	(1)	05/04/2026		C		42,341	(1)	(1)	(1)	Common Stock	931,502	(1)	0	I	See footnotes ⁽²⁾⁽³⁾
Series B Preferred Stock	(1)	05/04/2026		C		18,146	(1)	(1)	(1)	Common Stock	399,212	(1)	0	I	See footnotes ⁽²⁾⁽⁴⁾
Series C Preferred Stock	(1)	05/04/2026		C		56,972	(1)	(1)	(1)	Common Stock	1,253,384	(1)	0	I	See footnotes ⁽²⁾⁽³⁾

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series C Preferred Stock	(1)	05/04/2026		C			10,054	(1)	(1)	Common Stock	221,188	(1)	0	I	See footnotes ⁽²⁾⁽⁵⁾

1. Name and Address of Reporting Person*
[RA CAPITAL MANAGEMENT, L.P.](#)

(Last) (First) (Middle)
[200 BERKELEY STREET, 18TH FLOOR](#)

(Street)
[BOSTON MA 02116](#)

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[RA Capital Healthcare Fund LP](#)

(Last) (First) (Middle)
[C/O RA CAPITAL MANAGEMENT, L.P.
200 BERKELEY STREET, 18TH FLOOR](#)

(Street)
[BOSTON MA 02116](#)

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[RA Capital Nexus Fund II, L.P.](#)

(Last) (First) (Middle)
[C/O RA CAPITAL MANAGEMENT, L.P.
200 BERKELEY STREET, 18TH FLOOR](#)

(Street)
[BOSTON MA 02116](#)

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[RA Capital Nexus Fund IV, L.P.](#)

(Last) (First) (Middle)
[C/O RA CAPITAL MANAGEMENT, L.P.
200 BERKELEY STREET, 18TH FLOOR](#)

(Street)
[BOSTON MA 02116](#)

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[Kolchinsky Peter](#)

(Last) (First) (Middle)
[C/O RA CAPITAL MANAGEMENT, L.P.
200 BERKELEY STREET, 18TH FLOOR](#)

(Street)
[BOSTON MA 02116](#)

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[Shah Rajeev M.](#)

(Last)	(First)	(Middle)
C/O RA CAPITAL MANAGEMENT, L.P.		
200 BERKELEY STREET, 18TH FLOOR		
<hr/>		
(Street)		
BOSTON	MA	02116
<hr/>		
(City)	(State)	(Zip)

Explanation of Responses:

- Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
- RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II") and RA Capital Nexus IV Fund, L.P. (the "Nexus Fund IV"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- Held directly by the Fund.
- Held directly by Nexus Fund II.
- Held directly by Nexus Fund IV.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$24.00 to \$24.9994 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$23.495 to \$24.455 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$24.505 to \$25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Dr. Laura Tadvalkar, a Managing Director of the Adviser, serves on the Issuer's board of directors.

<u>/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.</u>	<u>05/06/2026</u>
<u>/s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC the General Partner of RA Capital Healthcare Fund, L.P.</u>	<u>05/06/2026</u>
<u>/s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund II GP, LLC, the General Partner of RA Capital Nexus Fund II, L.P.</u>	<u>05/06/2026</u>
<u>/s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund IV GP, LLC, the General Partner of RA Capital Nexus Fund IV, L.P.</u>	<u>05/06/2026</u>
<u>/s/ Peter Kolchinsky, individually.</u>	<u>05/06/2026</u>
<u>/s/ Rajeev Shah, individually.</u>	<u>05/06/2026</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.